Related Experiment Videos
Life-threatening hyponatremia caused by vinblastine
G Zavagli1, G Ricci, G Tataranni
1Istituto di Patologia Medica, Università di Ferrara, Italy.
Medical Oncology and Tumor Pharmacotherapy
|January 1, 1988
Summary
A patient experienced a neurotoxic crisis and severe hyponatremia after ABVD chemotherapy. Vinblastine likely caused this by triggering inappropriate ADH release and a novel kidney tubular lesion.
Area of Science:
- Oncology
- Nephrology
- Pharmacology
Background:
- ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) is a chemotherapy regimen used for lymphoma.
- Neurotoxic complications can occur during chemotherapy treatment.
Observation:
- A patient with immunoblastic lymphoma developed a neurotoxic crisis and severe hyponatremia (104 mEq/L) after ABVD administration.
- The patient exhibited high urinary concentrations of tubular enzymes, indicating kidney tubular damage.
- Despite low plasma osmolality, antidiuretic hormone (ADH) levels were detectable.
Findings:
- Vinblastine is implicated as the cause of hyponatremia through two mechanisms.
- Mechanism 1: Inappropriate release of ADH, a known side effect.
- Mechanism 2: A previously unreported tubular lesion impairing sodium and solute reabsorption.
Implications:
- This case highlights a novel mechanism of chemotherapy-induced hyponatremia.
- Early recognition of tubular dysfunction is crucial in managing such adverse events.
- Further research into vinblastine's nephrotoxic effects is warranted.